Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 14:3:253.
doi: 10.3389/fimmu.2012.00253. eCollection 2012.

Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development

Janis Ancans  1
Affiliations

Cell therapy medicinal product regulatory framework in Europe and its application for MSC-based therapy development

Janis Ancans. Front Immunol. .

Abstract

Advanced therapy medicinal products (ATMPs), including cell therapy products, form a new class of medicines in the European Union. Since the ATMPs are at the forefront of scientific innovation in medicine, specific regulatory framework has been developed for these medicines and implemented from 2009. The Committee for Advanced Therapies (CAT) has been established at the European Medicines Agency (EMA) for centralized classification, certification and evaluation procedures, and other ATMP-related tasks. Guidance documents, initiatives, and interaction platforms are available to make the new framework more accessible for small- and medium-sized enterprises, academia, hospitals, and foundations. Good understanding of the centralized and national components of the regulatory system is required to plan product development. It is in the best interests of the cell therapy developers to utilize the resources provided starting with the pre-clinical stage. Whilst there have been no mesenchymal stem cell (MSC)-based medicine authorizations in the EU, three MSC products have received marketing approval in other regions since 2011. The information provided on the regulatory requirements, procedures, and initiatives is aimed at facilitating MSC-based medicinal product development and authorization in the EU.

Keywords: Committee for Advanced Therapies; Hospital Exemption; advanced therapy medicinal product; cell therapy medicinal product; mesenchymal stem/progenitor cell; national competent authority.

PubMed Disclaimer

References

    1. Buchholz C. J., Sanzenbacher R, Schüle S. (2012). The European hospital exemption clause – new option for gene therapy? Hum. Gene Ther. 23 7–12 - PubMed
    1. Committee for Advanced Therapies (CAT), and CAT Scientific Secretariat. (2010). Challenges with advanced therapy medicinal products and how to meet them. Nat. Rev. Drug Discov. 9 195–201 - PubMed
    1. Eichler H. G., Oye K., Baird L. G., Abadie E., Brown J., Drum C. L., Ferguson J., Garner S., Honig P., Hukkelhoven M., Lim J. C., Lim R., Lumpkin M. M., Neil G., O’Rourke B., Pezalla E., Shoda D., Seyfert-Margolis V., Sigal E. V., Sobotka J., Tan D., Unger T. F., Hirsch G. (2012). Adaptive licensing: taking the next step in the evolution of drug approval. Clin. Pharmacol. Ther. 91 426–437 - PubMed
    1. Li T. S., Cheng K., Malliaras K., Smith R. R., Zhang Y., Sun B., Matsushita N., Blusztajn A., Terrovitis J., Kusuoka H., Marbán L, Marbán E. (2012). Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J. Am. Coll. Cardiol. 59 942–953 - PMC - PubMed
    1. Mahalatchimy A., Rial-Sebbag E., Tournay V., Faulkner A. (2012). The legal landscape for advanced therapies: material and institutional implementation of European Union Rules in France and the United Kingdom. J. Law Soc. 39 131–149 - PubMed